Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
Avid Bioservices (NASDAQ:CDMO, CDMOP) announced participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, taking place on March 23-24, 2021. CEO Nick Green will feature in a fireside chat on March 24 at 4:15 PM Eastern. The forum will be held virtually, providing a platform for Avid to showcase its commitment to high-quality biologics contract development and manufacturing services. Avid specializes in CGMP manufacturing for biopharmaceuticals, leveraging 28 years of experience in the industry.
- None.
- None.
TUSTIN, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum. Nick Green, president and chief executive officer of Avid Bioservices, will be the featured speaker in a fireside chat at the conference, which will take place March 23-24, 2021 in a virtual format.
Details of the company’s participation are as follows:
- KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
Conference Date: March 23-24, 2021
Fireside Chat Time/Date: 4:15 p.m. Eastern on Wednesday, March 24, 2021
Format: Virtual Conference
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 28 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com
FAQ
What is Avid Bioservices' participation in the KeyBanc Capital Markets Investor Forum?
When will Avid Bioservices' fireside chat take place?
What services does Avid Bioservices provide?
What is the focus of Avid Bioservices?
Where can I find more information about Avid Bioservices?
